A real-time and continuous brain monitoring system to record and track brain activity and extract biomarkers for neurological conditions

Información del proyecto

NS System

Identificador del acuerdo de subvención: 828551

DOI

10.3030/828551

Proyecto cerrado

Fecha de la firma de la CE 5 Septiembre 2018

Fecha de inicio 1 Septiembre 2018

Fecha de finalización 31 Diciembre 2018

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

NEUROSTEER LTD
Israel

Periodic Reporting for period 1 - NS System (A real-time and continuous brain monitoring system to record and track brain activity and extract biomarkers for neurological conditions)

Período documentado: 2018-09-01 hasta 2018-12-31

Resumen del contexto y de los objetivos generales del proyecto

Neurosteer is an Israeli neurotechnology company founded in 2015 with the mission to become the leading player in neurological monitoring. Neurosteer offers a revolutionary medical-grade, real-time brain sensing platforms for a wide range of medical, wellness and lifestyle applications. The technology combines advanced neuroscience and proprietary machine learning algorithms to capture brain activity and interprets brain dynamics to detect cognitive states and neurological conditions. Its first product, NS System, uses unique and flexible electronics combined with advanced signal processing (Harmonic Analysis) and machine learning technique to extract in real time the neurological biomarkers related to early and advanced detection of cognitive impairments.
The team is now working towards developing an upgraded system able to increase the sensitivity of the EEG measurements capturing even very weak signals (nV) from frontotemporal lobes. The key objectives of the development are to optimise the NS System software analysis system for biomarkers’ extraction and early detection of cognitive disorders; to set-up a production line with an external Contract Manufacturer (CMO); to clinically validate the product through a large multicentre study and to obtain CE mark and certification of the system as a medical device.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Throughout the duration of the project, Neurosteer defined the users’ requirements for software implementation, defined the software specifications and reviewed its development plan, and scouted for hospitals and Contract Manufacturer (CMO) to support in the validation and production stages. The market segments and opportunities have also been evaluated, defining the TAM and SAM. Neurosteer established a commercialisation strategy. The Phase 1 feasibility assessment has established that a development plan for the NS System is technically and commercially viable, and that implementation of a commercialisation plan should be pursued. SME Instrument Phase 2 funding could provide the correct amount of funding and support to allow the stated activities to be implemented successfully

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The global population aged more than 60 years numbered 962 million in 2017 and the number of older persons is expected to double again by 2050, when it is projected to reach nearly 2.1 billion. Neurodegenerative diseases such as Dementia, Alzheimer’s and Parkinson’s are debilitating and largely untreatable conditions that are strongly linked with age. Amongst these disorders, the dementias are responsible for the greatest burden of disease, with Alzheimer’s disease and related disorders affecting over 7 million people in Europe, and this figure is expected to double every 20 years as the population ages. It currently costs approximately €130 billion per annum to care for people with dementia across Europe, highlighting age-related neurodegenerative disease as one of the leading medical and societal challenges faced by EU society. Recent advancements in brain monitoring technologies, big-data analysis and genetics have paved the way for the development of innovative solutions to assess brain neurodegeneration at a very early stage. In fact, early detection of cognitive disorders will provide valuable data on the progression of the disorders at the earliest stage. Also, using big data analytics tools will guarantee better ways to combat the disorder well before it becomes a debilitating problem. In turn, early detection of cognitive disorders will lead to hug cost-savings implications - €7 trillion total savings - in health and long-term care expenditures.
Neurosteer fully embraces this opportunity being the first and unique medical-EEG that is capable of accurate analysing brain signals and perform an early and advanced detection of cognitive disorders. NS System will provide a long-awaited response to the neurological monitoring market demand for cost-effective and accurate diagnostic devices.

NS System